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Background: Hepcidin, encoding by HAMP gene, is the pivotal regulator of iron metabolism, controlling the systemic
absorption and transportation of irons from intracellular stores. Abnormal levels of HAMP expression alter plasma iron
parameters and lead to iron metabolism disorders. Therefore, it is an important goal to understand the mechanisms
controlling HAMP gene expression.
Results: Overexpression of Sox2 decrease basal expression of HAMP or induced by IL-6 or BMP-2, whereas, knockdown
of Sox2 can increase HAMP expression, furthermore, two potential Sox2-binding sites were identified within the human
HAMP promoter. Indeed, luciferase experiments demonstrated that deletion of any Sox2-binding site impaired
the negative regulation of Sox2 on HAMP promoter transcriptional activity in basal conditions. ChIP experiments
showed that Sox2 could directly bind to these sites. Finally, we verified the role of Sox2 to negatively regulate
HAMP expression in human primary hepatocytes.
Conclusion: We found that Sox2 as a novel factor to bind with HAMP promoter to negatively regulate HAMP
expression, which may be further implicated as a therapeutic option for the amelioration of HAMP-overexpression-related
diseases, including iron deficiency anemia.
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Hepcidin, encoding by HAMP gene, is the key regulator of
iron homeostasis, and is a small, defensin-like peptide pro-
duced by the liver [1,2]. HAMP expression is tightly regu-
lated by many signals including iron content, erythropoietic
activity, and inflammation [3-5]. The expression of the
HAMP is increased in patients with anemia of chronic dis-
ease. Anemia of chronic disease (ACD), also known as
anemia of inflammation, is the most prevalent type of
anemia in hospitalized patients worldwide [6,7]. The patho-
genesis of ACD is characterized by iron-restricted erythro-
poiesis, whereas iron is retained in the macrophages
leading to the disorder of total body iron [8,9]. It has now
become clear that inflammatory cytokines released during
acute infection or chronic disease can alter systemic iron
metabolism by inducing excess synthesis of hepcidin* Correspondence: li_gang169@163.com; gangjinsh@yeah.net
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unless otherwise stated.[4,7,8,10]. Treatment of anemia, when necessary, has in-
cluded administration of iron, packed red cell transfusion,
or erythropoiesis-stimulating agents. However, concerns
over adverse effects of these therapies, including iron over-
load, increased risk of infection, recurrence of cancer, and
cardiovascular complications, have driven the need for al-
ternative treatments [7,11,12]. Due to the central role of
HAMP as described above, inhibition of its biological activ-
ity or its expression level may be promising new ap-
proaches for the treatment of anemia associated disease.
Sox2 is a member of the Sox family of transcription
factors. This protein family shares highly conserved
DNA binding domains known as HMG (High-mobility
group) box domains containing approximately 80 amino
acids [13]. Sox2 is essential for maintaining self-renewal,
or pluripotency, of undifferentiated embryonic stem cells
[14-16]. We analyzed the HAMP promoter region and
putative Sox2 binding sites were identified, suggesting
that Sox2 maybe play roles to regulate HAMP expres-
sion. In current study, we found that Sox2 functions as
the negative regulator to bind with the HAMP promoterhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Song et al. Biological Research  (2015) 48:23 Page 2 of 8to control the HAMP expression. Overexpression of
Sox2 in Huh7 cells or HepG2 cells can significantly de-
crease HAMP expression; in contrast, knockdown Sox2
with siRNA can further increase HAMP expression. We
also identified two putative Sox2 binding sites in HAMP
promoter and generated the HAMP promoter driven lu-
ciferase reporter construct. With this reporter construct,
we found that both the Sox2 binding sites are required
for Sox2 to exert its negative regulation on HAMP ex-
pression; we demonstrated that Sox2 can directly bind
with the putative binding sites with ChIP assay. Finally,
we also found that Sox2 can downregulate HAMP ex-
pression in primary hepatocytes.
In conclusion, our study presents important evidence
for the regulation of HAMP expression by Sox2, and this
finding can supply a potential therapeutic option to treat
anemia of chronic disease.
Results and discussion
Overexpression of Sox2 decrease HAMP expression in
hepatoma-derived cells
We searched HAMP expression with BioGPS database
(http://biogps.org/) and the analysis suggest that HAMP is
highly and specifically expressed in liver tissue (Additional
file 1: Figure S1). This result is validated in many cell lines
from different tissues with by RT-qPCR assay. As shown in
Additional file 1: Figure S2, HAMP is highly expressed in
cell lines derived from hepatocytes.
Anemia of chronic disease is a condition caused by
increased HAMP production, and is a result of inflam-
mation [7,8]. The central role of HAMP in the mainten-
ance of iron homeostasis suggests that targeting of this
peptide may result in therapeutic treatments of iron-
overload disorders, so we analyzed the promoter region,
aiming to find the transcription factor to control HAMP
expression. TFsearch program (http://www.cbrc.jp) and
TESS Tool (http://www.cbil.upenn.edu/cgi-bin/tess/tess)
analysis suggest that putative Sox2 binding sites were
identified in this region, thus, we hypothesize that Sox2
can control the expression of HAMP.
To examine the regulation of Sox2 on HAMP, we
transfected Huh7 cells with increasing doses of plasmids
expressing Myc-Sox2 and RNA was extracted from
Huh7 cells and then analyzed HAMP expression level
with RT-qPCR assay at 48 h posttransfection. We found
that overexpression of Sox2 can dramatically reduce
HAMP expression in Huh7 cells in a dose dependent
manner (Figure 1A). To exclude our observation is cell
specific, we also performed this assay in HepG2 cells,
and we observed the similar phenomenon (Additional
file 1: Figure S3).
It was reported that IL-6 and BMP-2 could up-regulates
transcription of HAMP [5,17]. To further evaluate the
inhibitory effect of Sox2 on HAMP expression, wetransfected Sox2 into Huh7 cells prior to IL-6 or BMP-2
stimulation, and RT-qPCR assay was performed to deter-
mine HAMP expression, as presented in Figure 1B and C,
treatment of IL-6 or BMP-2 led to an average of 7.8 or 4.7
folds increase of HAMP, respectively, but this was signifi-
cantly impaired in Sox2 transfected Huh7 cells, which sug-
gest that Sox2 can inhibit IL-6 or BMP-2 induced HAMP
expression (Additional file 1: Figure S4).
Knockdown of Sox2 increase HAMP expression in
hepatoma-derived cells
To further test the role of Sox2 in regulation of HAMP
expression, we knockdown Sox2 with siRNA prior to
stimulation of Huh7 cells with IL-6 or BMP-2. Sox2
knockdown efficiency and HAMP expression were de-
termined with Western Blotting assay (Figure 2A) or
RT-qPCR assay. As illuminated in Figure 2B and C, IL-6
or BMP-2 can induce the expression level of HAMP
about 6.0 or 4.1 folds respectively, and IL-6 or BMP-2
induced HAMP expression was further enhanced in
Sox2 knockdown Huh7 cells (9.1 or 8.2 folds respect-
ively), and knockdown of Sox2 can also slightly in-
creased HAMP expression in the IL-6 and BMP-2
untreated cells. Taken together, all the data presented
here support that Sox2 function as the negative regula-
tor to control the HAMP expression. In the following
assay, we ought to dissect the molecular mechanism of
Sox2 regulation on HAMP expression.
Sox2 regulate HAMP reporter activity
To map the region in the HAMP promoter responsible for
Sox2 exertion on HAMP transcriptional control, we ana-
lyzed the DNA sequences 1,000-bp upstream of HAMP
start codon by TFsearch program (http://www.cbrc.jp) and
TESS Tool (http://www.cbil.upenn.edu/cgi-bin/tess/tess).
Two putative Sox2 binding sites were identified (Figure 3A).
To confirm this bioinformatical result, we constructed a
series of HAMP promoters (Figure 3B) upstream of a pro-
moterless luciferase ORF in the pGL3-enhancer vector.
The engineered HAMP-Luc plasmids were transfected into
Huh7 cells together with Myc-Sox2 or not. The luciferase
activities were measured to determine the HAMP promoter
activity. As shown in Figure 3C, Sox2 can decrease HAMP
promoter activity about 3.2 folds; in order to validate the
roles of the potential Sox2 binding sites (highlighted in
Figure 3A) in the HAMP promoter for Sox2 mediated
regulation on HAMP expression, we individually or com-
pletely deleted the potential Sox2 binding sites, and then
transfected them into Huh7 cells with or without Sox2.
The data suggested that deletion of any Sox2 putative
binding sites compromised Sox2 mediated decrease of
HAMP promoter activity, and the Sox2 mediated inhibi-
tory effect was completely impaired if both of the Sox2
putative binding sites were deleted, suggesting that both
Figure 1 Overexpression of Sox2 can negatively regulate HAMP
expression in Huh7 cells. (A) Huh7 cells were transfected with an
increasing amount of plasmids expressing Myc-Sox2 (pcDNA3.1-Myc
vector was used to balance the DNA to the same quantity in each
group), and cell were harvested for RT-qPCR assay to determine HAMP
expression and also cell lysates were analyzed with immunoblotting
with the anti-Myc or anti-actin antibodies at 48 h post-transfection.
(B-C) Huh7 cells were transfected with the plasmids expressing
Myc-Sox2. Forty-eight hours later, cells were stimulated with IL-6
(B) or BMP-2 (C) for additional 6 hours. And cells were harvested for
RNA extraction to determine HAMP expression and some cell lysates
were immunoblotted with the anti-Myc antibody to analyze the
Myc-Sox2 expression. The experiments were repeated for three times
with similar results and data were shown as means ± SE. Statistical
analyses were conducted using one-way ANOVA with Tukey’s multiple
comparison test. Significant differences are indicated by *p < 0.05.
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Sox2 can directly bind with HAMP promoter
To further analyze the binding of Sox2 with HAMP pro-
moter, we performed ChIP assay. We transfected Myc-
Sox2 into Huh7 cells and then harvested cells at 48 h
post-transfection. Cells were processed and the cell ly-
sates were immunoprecipitated with antibodies for Myc
or isotype lgG, followed by qPCR using the primer sets
(SB primers) specifically for the HAMP promoter se-
quence to quantify the amount of the HAMP bound
DNA, and another primer sets (SB primer(out)) outside
of the Sox2 putative binding sites were also used for the
qPCR assay for control. As shown in Figure 3D, the
amount of HAMP promoter precipitated by Myc in-
creased for about 4-fold as compared to the isotype lgG
control. These results revealed direct and specific bind-
ing of Sox2 to cis-regulatory sequences in the HAMP
promoter region.
Sox2 negatively regulate HAMP expression in primary
hepatocytes
Finally, we sought to determine whether our observa-
tions could be verified in human primary hepatocytes.
Firstly, we transduced the primary hepatocytes with
lentivirus expressing Myc-Sox2. Cells were collected at
72 h postinfection and Immunoblotting assay was per-
formed to analyze the expression of Myc-Sox and total
intracellular RNA was extracted for RT-qPCR assay to
detect the expression of HAMP. We found that lentivirus
could efficiently transduce Myc-Sox2 expression in primary
hepatocytes and overexpression of Myc-Sox2 could de-
crease HAMP expression with an average of 3 folds in pri-
mary hepatocytes (Figure 4A). Furthermore, we infected
primary hepatocytes with shRNA targeting Sox2, cells were
collected at 72 h postinfection, and RT-qPCR assay was
performed to determine Sox2 knockdown efficiency and
HAMP expression, as shown in Figure 4B and C,
Figure 2 Knockdown of Sox2 can further increase HAMP expression
in Huh7 cells. (A) Huh7 cells were transfected with Sox2-targeting
siRNAs and control siRNA. Western blot analysis of partial Sox2
knockdown cells was performed to evaluate the Sox2 knockdown
efficiency. (B-C) Huh7 cells transfected with Sox2 siRNAs were treated
with IL-6 or BMP-2 were subjected for RNA isolation to determine
HAMP expression with RT-qPCR assay. The experiments were repeated
for three times with similar results and data were shown as means ±
SE. Statistical analyses were conducted using one-way ANOVA with
Tukey’s multiple comparison test. Significant differences are indicated
by *p < 0.05.
Figure 3 Sox2 binds with HAMP promoter to regulate its expression.
(A) Two putative Sox2 binding sites were indicated with open boxes.
(B) Schematic diagram of a series of HAMP promoter luciferase
reporter constructs and putative Sox2 binding sites were marked.
(C) Huh7 cells were cotransfected with various HAMP promoter
luciferase reporter plasmids and the internal control plasmid pRL-TK,
together with Myc-Sox2 or not. Forty-eight hours later, the cell lysates
were subjected to dual luciferase assay, and the results were expressed
as fold induction of luciferase activity relative to the empty vector
without Myc-Sox2 expression. The error bar represented three
replicates. (D) Huh7 cells transfected with Myc-Sox2 for 48 h were
cross-linked, and sonicated to generate chromatin fragments. The
sheared chromatins were immunoprecipitated with monoclonal
antibodies against Myc or a mouse IgG isotype control followed by
qPCR analysis using the primer set flanking the HAMP promoter.
The data were expressed as the percentage of immunoprecipitated
chromatin DNA versus the total input. The experiments were repeated
for three times with similar results and data were shown as means ±
SE. Statistical analyses were conducted using a one-way ANOVA with
Tukey’s multiple comparison test to determine individual p-values
(C) or an unpaired, two-tailed student t-test (D). Significant
differences are indicated by *p < 0.05.
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Figure 4 Sox2 negatively regulate HAMP2 expression in primary
hepatocytes. Primary hepatocytes were cultured and lentivirus
expressing Myc-Sox2 (A) or shRNA targeting Sox2 (B and C) infected
the cells. Cells were harvested at 72 h later for Western blotting
assay and RT-qPCR assay to determine Myc-Sox2 expression, HAMP
expression and Sox2 knockdown efficiency. The experiments were
repeated for three times with similar results and data were shown as
means ± SE. Statistical analyses were conducted using a one-way
ANOVA with Tukey’s multiple comparison test to determine individual
p-values (B-C) or an unpaired, two-tailed student t-test (A). Significant
differences are indicated by *p < 0.05.
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HAMP expression level more than 4 folds in primary
hepatocytes. Collectively, all the data demonstrated that
Sox2 function as a negative regulator to control HAMP
expression.
HAMP is a small, disulfide-rich peptide produced pre-
dominantly by the liver, and plays an important role in
regulating systemic iron metabolism in mammals [18,19].
Under physiological conditions, the expression of HAMP
is regulated by numerous factors [20]. The known positive
regulators are the TfR2 (transferrin receptor 2) [21,22],
hereditary HFE (haemochromatosis) protein [21], BMPs
(bone morphogenetic proteins) [17,23,24] and HJV
(haemojuvelin) [23-26]. One of negative regulators of
liver hepcidin expression is Matriptase-2, a transmem-
brane serine protease, inhibits the expression of HAMP
by interacting with membrane HJV and cleaving it into
fragments [27-29]. In previous study, SMAD7 was iden-
tified as another negative regulator of HAMP gene ex-
pression [30]. SMAD7 is an inhibitory SMAD protein
that mediates a negative feedback loop to both TGF-β
(transforming growth factor β) and BMP signaling [31].
Sox2 is a member of the SOXB1 subfamily of high-
mobility group box proteins and plays a key role in re-
programming somatic cells into pluripotent stem cells
and neural stem cells in culture [16,32-35]. Our present
study further demonstrates that Sox2 can negatively
regulate the expression of HAMP, suggesting that Sox2
might be an important factor to control HAMP expres-
sion level to regulate systemic iron metabolism.
In the present study, we found that overexpression of
Sox2 can decrease HAMP expression in hepatoma derived
cells, and Sox2 can further downregulate IL-6 or BMP-2
induced HAMP expression in these cells (Additional file
1: Figure S4); in contrast, knockdown of Sox2 significantly
increase HAMP expression in these cells. All the data sup-
port Sox2 as a negative regulator to control HAMP ex-
pression. We further constructed HAMP promoter driven
reporter system and two putative Sox2 binding sites were
identified in the promoter region. We found that the Sox2
binding sites are required for Sox2 to exert its inhibitory
effect on the expression of HAMP, and ChIP assay also
suggested that Sox2 can directly bind with the HAMP
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that the overexpression of Sox2 in human primary hepato-
cyte cells decreased HAMP expression, whereas knock-
down Sox2 can enhance the expression of HAMP.
Moreover, the negative regulation of Sox2 on HAMP
should be verified in vivo to evaluate its role in the iron
metabolism disorder, which is induced by high expression
of HAMP. The molecular mechanism of Sox2 regulation
of HAMP expression is unknown, and Sox2 has been
found to upregulate Rex1 and Nanog with Oct3/4 [36,37].
In this study, we found that Sox2 function as the negative
regulator for HAMP expression, which is different from
the previous findings. In addition to Oct3/4, Sox2 was
found to interact with other molecules, such as Pax6 [38]
or NPM1 [39]. The different regulation of Sox2 on the tar-
get genes may be dependent on the components of the
Sox2 associated complex in the nucleus.
Our discovery shed more light on the transcriptional
regulation of HAMP by Sox2 and facilitates understanding
the underlying mechanisms of maintaining body iron
homeostasis. Interventions targeting this pathway could
be useful for therapy of the resulting iron metabolism
disorders.
Conclusion
We found that Sox2 as a novel factor to bind with
HAMP promoter to negatively regulate HAMP expres-
sion, which may be further implicated as a therapeutic
option for the amelioration of HAMP-overexpression-
related diseases, including iron deficiency anemia.
Methods
Cell culture
HEK293 cells, Huh7 cells, A549 cells, BxPC-3 cells, Hela
cells, SV-HUC-1 cells, SW1353 cells and RWPE-2 cells,
were grown in DMEM medium (Invitrogen, Carlsbad,
CA, USA) containing L-glutamine, supplemented with
10% (vol/vol) heat-inactivated fetal calf serum, penicillin
(100 units/ml), and streptomycin (100 mg/ml). The hu-
man hepatoma HepG2 cells were grown in RPMI 1640
media (Gibco) supplemented with the same components
as mentioned above.
Plasmid construction
To make the Myc-Sox2 expression construct, the cDNA
encoding human Sox2 was cloned (nucleotide 438 nt to
1391 nt, GenBank Accession: NM_003106) into pcDNA3-
Myc vector; and then the Myc-Sox2 was cloned into
pLVX- IRES-Puro lentivirus vector to generate the
pLVX-Myc-Sox2-IRES-Puro construct. To construct
the HAMP promoter driven luciferase reporter plasmid
(HAMP-Luc), a 1,000-bp sequence upstream of the
translation start codon was amplified from genomic
DNA of Huh7 cells using primers containing KpnI andHindIII sites. The PCR product was then cloned into
pGL3-enhancer vector (Promega, Madison, WI, USA)
[40]. All the Sox2 binding sites deleted mutants were
generated by QuikChange® Site-Directed Mutagenesis
Kit (Stratagene, La Jolla, CA, USA). All constructs were
verified by DNA sequencing analysis. The primer infor-
mation is available upon request.
Transfection assay
Plasmid expressing Myc-Sox2, HAMP-Luc or siRNA tar-
geting human Sox2 were transfected into target cells
with Lipofectamine™ 2000 (Invitrogen) following manu-
facture’s instruction.
Lentiviruses expressing the Myc-Sox2 were obtained
by co-transfecting pLVX-Myc-Sox2-IRES-Puro with the
packaging and envelope vectors into HEK293T cells.
Viral supernatants were harvested 48 h post transfection,
filtered and used to infect primary hepatocytes.
Immunoblot analysis
For western blot analysis, the cells were lysed in sample
buffer (20 mM Tris–HCl, pH7.5, 150 mM NaCl, 1 mM
EDTA, 1% NP40) containing Complete Protease Inhibi-
tor Cocktail (Roche) and then incubated at 95°C for
10 min. Cell lysates were cleared by centrifugation and
supernatants were separated by SDS–PAGE and ana-
lyzed by immunoblotting. The Luminata Forte Western
HRP Substrate (Millipore) was used for the development
of positive signals. The antibodies used in this study
include Sox2(Abcam, #ab97959), Myc (Cell Signaling
#9402) and beta-Actin (Cell Signaling #4970).
RNA isolation and quantitative RT-PCR
RNA was isolated by TRIzol® Reagent (Life Technologies)
in according to the manufacturer’s protocol. RNA pellets
were resuspended in diethylpyrocarbonate (DEPC)-treated
water and the RNA concentration was determined using
the NanoDrop®ND-1000 spectrophotometer (Thermo
Scientific). Complementary DNA (cDNA) was synthe-
sized from 1 μg of RNA using random hexmers and
TaqMan® Reverse Transcription Reagents (Applied Bio-
systems, Roche, NJ, USA) and amplified using primers
specific for GAPDH (forward: 5′-GAA GGT GAA GGT
CGG AGT C-3′; reverse: 5′-GAA GAT GGT GAT
GGG ATT TC-3′ . Accession NO.: NM_002046; the
length of the amplicon is 226 bp), and HAMP (forward:
5′- CGC TTG CCT CCT GCT CCT-3′; reverse:
5′- CTC GCC TCC TTC GCC TCT-3′. Accession NO.:
NM_021175; the length of the amplicon is 152 bp) using
SYBR® Green Real time PCR Master Mix (TOYOBO,
Osaka, Japan). The specificity is determined by the melt
curve analysis. For the data analysis, the Ct (threshold
cycle) values for the gene of interested were normalized
to those for GAPDH.
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Ten thousand Huh7 cells were seeded into 48-well plates
overnight prior to transfection with 20 ng/well of HAMP-
Luc constructs and 10 ng/well of CMV promoter driven
Renilla luciferase vector (pRL-CMV; Promega) together
with Myc-Sox2 (0.5ug/well) or not. The cells were har-
vested 24 h later and cell lysates were assayed for luciferase
activities using the Dual-Luciferase Reporter Assay System
(Promega) following the manufacturer’s instructions.
ChIP assay
Huh7 cells were transfected with Myc-Sox2 and cells were
harvested at 48 h posttransfection. Cells were cross-linked,
and sonicated to generate chromatin fragments according
to a previously described protocol [41]. In particular, the
cells were crosslinked with 1% formaldehyde, then lysed
and sonicated to shear DNA. Sheared chromatins were
then precleaned with protein A agarose. 20% of the sheared
chromatins were kept as “input control”. The rest were in-
cubated with antibodies against Myc (Sigma-Aldrich) or
normal mouse IgG isotype control followed by additional
incubation with protein A agarose. The bead-bound
protein-DNA complexes were eluted and crosslinks were
reversed. Precipitated DNA was subjected to qPCR using
the HAMP promoter primers: 5′-CCA TAT TAC TGC
TGT CAT TTA T-3′ and 5′-CAG TGT CAG ACC CTT
GAG ATG-3′, and the control primers which were up-
stream of the Sox2 binding sites as the control: 5′-TTG
CCC AGG CTA GTC TTG AA-3′ and 5′-AGC ACA
GTG GCT TAT GCC TG-3′. Enrichment values were nor-
malized with corresponding input control.
Knockdown assay
For siRNA experiments, siRNA targeting human Sox2
(1#: 5′-GGT TGA CAC CGT TGG TAAT-3′; 2#:5′-TGC
CGA GAA TCC ATG TATA-3′) was transfected into tar-
geting cells and cells were harvested at indicated time point
for further assay. Non-specific oligonucleotides (5-GATCT
GATCGACACTGTAATG-3) with no significant homology
to any mammalian gene sequence were used as non-
silencing controls in all experiments.
Double-stranded oligonucleotides targeting human Sox2
were cloned into the pLSLG lentiviral vector. The se-
quences targeting human Sox2 are the same with siRNA
sequence. HEK293T cells were transfected with the respect-
ive lentiviral vectors and packaging vectors to ensure
proper viral packaging. Viral supernatants were harvested
48 h post transfection, filtered and used to infect primary
hepatocyte cells to knockdown Sox2.
Primary human hepatocytes culture, and lentivirus
infection
Human hepatocytes, purchased from PromoCell, were
maintained in Hepatocyte Growth Medium (PromoCell,HD, GRE). Cells were plated at a density of 1 × 105 cells
on 48-well plates coated with type 1 collagen. The pro-
duced lentiviruses for Myc-Sox2 transduction and Sox2
shRNA knockdown mentioned aboved were inoculated
to primary human hepatocytes. Three days later the
lentivirus-transduced cells were collected for RT-qPCR
analysis of HAMP expression.
Statistical analysis
Statistical analysis of the data was performed by using
the GraphPad Prism software (GraphPad Software). Spe-
cific tests are noted in figure legends.
Additional file
Additional file 1: Figure S1. HAMP expression profiles of cell types and
tissues. Data represent HAMP gene profiles for the indicated human
tissues and cell lines on the BioGPS Gene portal (biogps.org/) indicate
that HAMP is highly and specifically expressed in liver. Figure S2. HAMP
expressed in hepatocyte-derived cells and primary hepatocytes with high
level. RT-qPCR assay was performed to determine HAMP mRNA expression.
Data were presented as the relative ratio of HAMP to GAPDH. The
experiments were repeated for three times and data were shown as
means ± SE. Figure S3. Overexpression of Sox2 can negatively regulate
HAMP expression in HepG2 cells. HepG2 cells were transfected with an
increasing amount of plasmids expressing Myc-Sox2 (pcDNA3.1-Myc
vector was used to balance the DNA to the same quantity in each group),
and RT-qPCR assay was performed to determine HAMP expression and also
cell lysates were analyzed with immunoblotting with the anti-Myc or
anti-actin antibodies at 48 h post-transfection. The experiments were
repeated for three times and data were shown as means ± SE. Statistical
analyses were conducted using one-way ANOVA with Tukey’s multiple
comparison test. Significant differences are indicated by *p < 0.05. Figure S4.
Overexpression of Sox2 can negatively regulate HAMP expression in Huh7
cells. Huh7 cells were transfected with the plasmids expressing
Myc-Sox2 (pcDNA3.1-Myc vector was used to balance the DNA to the
same quantity in each group). Forty-eight hours later, cells were stimulated
with IL-6 (A) or BMP-2 (B) for additional 6 hours. And RT-qPCR was performed
to determine HAMP expression and some cell lysates were immunoblotted
with the anti-Myc antibody to analyze the Myc-Sox2 expression. The
experiments were repeated for three times and data were shown as
means ± SE. Statistical analyses were conducted using one-way ANOVA
with Tukey’s multiple comparison test. Significant differences are
indicated by *p < 0.05.
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